Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine with anticonvulsant properties used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS). It is also used off-label for other seizure types.
## Primary Indications
* Adjunctive therapy for seizures in Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **LGS:** Initiate at 5 mg twice daily. Increase by 5-10 mg daily every week as needed. Maximum dose is 20 mg twice daily.
* **Other Seizure Types (Off-label):** Dosing varies widely and is not well-established. Common starting doses range from 5 mg to 15 mg daily, titrating to efficacy and tolerability. Maximum doses generally do not exceed 30 mg/day.
## Pediatric Dosing
* **LGS (2 years and older):**
* Initiate at 2.5 mg twice daily.
* Increase by 2.5-5 mg daily every week as needed.
* Maximum dose: 10 mg twice daily for patients weighing less than 30 kg, and 20 mg twice daily for patients weighing 30 kg or more.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Consider a lower starting dose and slower titration.
* **Renal Impairment:** Use with caution. Monitor for signs of accumulation.
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Acute narrow-angle glaucoma.
## Adverse Effects
Common adverse effects include somnolence, constipation, decreased appetite, fatigue, and aggression. Serious adverse effects include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, and withdrawal symptoms upon abrupt discontinuation.
## Key Drug Interactions
* **CYP3A4/CYP2C19 Inhibitors/Inducers:** Clobazam is a substrate of these enzymes. Concomitant use with strong inhibitors (e.g., ketoconazole, fluconazole) may increase clobazam levels. Concomitant use with strong inducers (e.g., rifampin, carbamazepine) may decrease clobazam levels.
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depressant effects may occur, increasing the risk of sedation, respiratory depression, and coma.
* **Other Anticonvulsants:** Potential for additive CNS depression. Monitor for efficacy and tolerability.
## Monitoring
* Seizure frequency and severity.
* Signs and symptoms of CNS depression (e.g., somnolence, dizziness).
* Signs of withdrawal upon dose reduction or discontinuation (e.g., anxiety, insomnia, seizures).
* Skin reactions.
* Liver function tests may be considered periodically.
## Clinical Pearls
* Clobazam should be titrated slowly to minimize adverse effects, especially somnolence.
* Abrupt discontinuation can lead to withdrawal symptoms, including seizures. Taper the dose gradually when discontinuing.
* Due to the risk of severe skin reactions, patients should be advised to seek immediate medical attention if a rash develops.
* The N-desmethylclobazam metabolite is active and has a longer half-life, contributing to accumulation with chronic use.
***
*Disclaimer: This information is intended for clinical professionals. Always consult the most current prescribing information and relevant guidelines before making clinical decisions.*
